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The use of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) alteration
present in 25 to 30% of breast cancers, has been associated with improved survival outcomes in both the adjuvant and metastatic
settings. However, despite the robust clinical efficacy of trastuzumab in HER2-positive metastatic breast cancer (MBC), primary and
secondary resistance remains a clinical challenge. Although lapatinib has demonstrated modest activity in this setting, trials reported to
date have yet to demonstrate improvements in overall survival with its use. Novel therapeutic strategies to circumvent trastuzumab
resistance are warranted, and agents targeting the HER, vascular endothelial growth factor, heat shock protein 90, phosphoinositide 3
kinase/Akt/mammalian target of rapamycin, and insulin-like growth factor-1 receptor pathways represent rational approaches in the
management of HER2-positive disease. In this review, early-phase and emerging trial data surrounding the use of these promising
agents in HER2-positive MBC will be discussed.
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The human epidermal growth factor receptor 2 (HER2) oncogene
is amplified and overexpressed in 25 to 30% of breast cancers and
has provided a basis for targeted therapeutics of this originally
poor-prognostic phenotype (Slamon et al, 1987; Slamon et al,
1989). Amplification of HER2 (ErbB2), a member of the ErbB/HER
family of receptor tyrosine kinases that also include epidermal
growth factor receptor (EGFR)/HER1/ErbB1, HER3/ErbB3 and
HER4/ErbB4, leads to increased receptor homo- and hetero-
dimerisation and subsequent activation of downstream signaling
pathways associated with cell proliferation, differentiation, survival
and angiogenesis (Yarden and Sliwkowski, 2001). Trastuzumab
(Herceptin; Genentech, South San Francisco, CA, USA), the first
available HER2-directed therapy, is a humanised monoclonal
antibody that targets the HER2 extracellular domain, and was
approved by the US Food and Drug Administration in 1998 for the
management of HER2-positive metastatic breast cancer (MBC) in
combination with chemotherapy. The anti-proliferative and
cytotoxic effects of trastuzumab likely result from a combination
of antibody-dependent cellular cytotoxicity, inhibition of extra-
cellular domain cleavage, decreased DNA repair, decreased
intracellular signal transduction and anti-angiogenic effects
(Spector and Blackwell, 2009). The pivotal phase-III trial of
trastuzumab plus chemotherapy in the first-line management of
HER2-positive MBC demonstrated robust improvements in
response rates (RRs; 50% vs 32%), median time to progression
(TTP; 7.4 vs 4.6 months) and median overall survival (25 vs
20 months) with the addition of trastuzumab (Slamon et al, 2001).
Nonetheless, primary and secondary resistance are frequently
encountered. Possible mechanisms include HER2 crosstalk with
other ErbB members or insulin-like growth factor-1 receptor
(IGF-1R) (Nahta et al, 2004), presence of p95-HER2, a truncated
receptor that lacks the extracellular binding domain for trastuzu-
mab (Scaltriti et al, 2007), PTEN deficiency (phosphatase and
tensin homologue deleted on chromosome 10) (Nagata et al, 2004),
increased phosphoinositide 3 kinase (PI3k)/Akt pathway activa-
tion (Berns et al, 2007) and, more recently, presence of Rac1, a
Ras-like small GTPase that affects trastuzumab-mediated endo-
cytosis of the ErbB2 receptor (Dokmanovic et al, 2009). Still, no
one mechanism has been defined in the clinic and it is not
clear that resistance to trastuzumab means a complete loss of
dependence on HER2 signaling.
Developing novel targeted agents for use in HER2-positive
breast cancer remains clinically significant. In this review,
strategies to overcome resistance to trastuzumab therapy (Figure 1)
will be discussed including novel antibody-based approaches
against HER2, newer ErbB-family tyrosine kinase inhibitors
(TKIs), anti-angiogenic therapies, heat shock protein 90 (hsp90)
inhibitors, PI3K and mammalian target of rapamycin (mTOR)
inhibitors, and IGF-1R inhibitors (Tables 1 and 2).
NEW ANTIBODY-BASED TARGETING OF HER2 –
PERTUZUMAB, TRASTUZUMAB DM1 (T-DM1)
Pertuzumab
Like trastuzumab, pertuzumab (Omnitarg, 2C4; Genentech) targets
the HER2 extracellular domain but at a different epitope, resulting
in inhibited dimerisation of HER2 with other HER family receptors
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www.bjcancer.com(EGFR/HER1, HER3 and HER4) (Agus et al, 2002). Preclinical
studies in HER2-positive breast cancer have demonstrated
promising antitumour efficacy with associated downregulation of
PI3K/Akt and MAPK signaling pathways both as a single-agent and
synergistically with trastuzumab (Nahta et al, 2004; Agus et al,
2002; Franklin et al, 2004; Scheuer et al, 2009). In a single-arm,
phase-II study of trastuzumab plus pertuzumab (every 3 weeks) in
11 patients with HER2-positive MBC and disease progression on
trastuzumab, an objective RR of 18% was reported, with partial
responses in 2 patients and stable disease in 3 patients (Portera
et al, 2008). The median TTP was 6 weeks. Using a lower limit left
ventricular ejection fraction (LVEF) cut-off of 55%, six cases of
left ventricular systolic dysfunction were seen (three grade 1,
two grade 2 and one grade 3) in this trial, raising concerns over
cardiotoxicity (Portera et al, 2008). In another single-arm phase-II
trial of trastuzumab (weekly or every 3 weeks (q3 weekly)) plus
pertuzumab (every 3 weeks) in 66 patients with trastuzumab-
refractory, HER2-positive MBC, a similar objective RR was also
demonstrated at 24.2%, including 5 patients with complete
response (7.6%) and 11 with partial response (16.7%) (Baselga
et al, 2010). Furthermore, stable disease X6 months was seen in an
additional 17 patients (25.8%), yielding a 50% clinical benefit rate
(CBR). The median progression-free survival (PFS) was 5.5 months
in this cohort. In contrast to the previous phase-II study,
cardiotoxicity was less of an issue despite the use of identical
drug doses in the q3 weekly regimen, with only three patients
experiencing an asymptomatic LVEF decline X10% and an
absolute LVEF o50%. In two out of the three patients, recovery
in LVEF was seen without treatment interruption, whereas the
third patient withdrew from the study because of progressive
disease. Overall, the trastuzumab/pertuzumab combination was
well tolerated, with diarrhoea (64%), fatigue (33%), nausea (27%)
and rash (26%) being the most common toxicities (Baselga et al,
2010). Ongoing trials are currently evaluating combinations of
pertuzumab with trastuzumab and chemotherapy in HER2-
positive MBC, including a phase-II trial of trastuzumab/capecita-
bine±pertuzumab in the second-line setting (PHEREXA;
NCT01026142) and a large global phase-III trial of trastuzumab/
docetaxel±pertuzumab in the first-line setting (CLEOPATRA;
NCT00567190). Combinations of pertuzumab with T-DM1
(discussed below) are also under investigation in multiple
phase-I–III studies.
T-DM1
T-DM1 (Genentech) represents a novel approach to drug delivery
in which the monoclonal antibody trastuzumab is conjugated to an
anti-microtubule agent (emtansine) (Lewis Phillips et al, 2008;
Junttila et al, 2010). In preclinical models, potent antitumour
activity was observed with T-DM1, including in trastuzumab- and
lapatinib-resistant states (Lewis Phillips et al, 2008; Junttila et al,
2010). In a phase-I study of T-DM1 in a heavily pretreated
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Figure 1 Targeted agents for HER2-positive MBC. Diagram depicting the molecular targets of approved and investigational agents for HER2-positive
MBC. Abbreviations: Akt, protein kinase B; c-kit, stem cell factor receptor; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor
receptor; hsp90, heat shock protein 90; IGF-1R, insulin-like growth factor-1 receptor; MBC, metastatic breast cancer; mTOR, mammalian target of
rapamycin; PDGFR, platelet-derived growth factor receptor; PI3K, phosphoinositide-3-kinase; RTK, receptor tyrosine kinase; TKI, tyrosine kinase inhibitor;
VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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median of four prior systemic agents, an encouraging clinical RR
of 44% was reported (Krop et al, 2010). At a maximum tolerated
dose of 3.6mgkg
 1 IV q3 weekly, T-DM1 was well-tolerated
overall with only mild toxicities (thrombocytopenia, transaminitis,
fatigue, nausea and anemia) and no reported cardiotoxicities.
In two phase-II trials of single-agent T-DM1 in a heavily pretreated
population, impressive RRs were similarly reported (Krop et al,
2009b; Burris et al, 2010). The first trial enrolled 112 patients with
HER2-positive MBC who had received a median of three prior
chemotherapy agents; the overall RR was 25.9%, and 24.2% in
those who had previously received both trastuzumab and lapatinib
(Burris et al, 2010). T-DM1 was well tolerated, with grade 3 or 4
hypokalemia (8.9%) and thrombocytopenia (8%) being the most
Table 1 Overview of novel therapeutic strategies under investigation for HER2-positive metastatic breast cancer
Agent Type
Phase of
development
a Clinical setting(s)
HER-targeted
Pertuzumab (Omnitarg) Monoclonal antibody III First-line and relapsed; combination with trastuzumab+chemotherapy
T-DM1 Antibody-drug conjugate III First-line and relapsed (after trastuzumab+taxane, after progression with X2 prior
HER2-targeted therapies); monotherapy, combination with pertuzumab
Lapatinib (Tykerb) Reversible TKI Approved Relapsed (after anthracycline, taxane, and trastuzumab); combination with capecitabine
III First-line; combination with letrozole (if hormone receptor positive)
First-line and relapsed; combination with chemotherapy or trastuzumab
Neratinib (HKI-272) Irreversible TKI III First-line and relapsed (after trastuzumab±chemotherapy); combination with
chemotherapy or trastuzumab
Afatinib (BIBW 2992) Irreversible TKI III First- and second-line (after trastuzumab+chemotherapy, after trastuzumab and/or
lapatinib progression); monotherapy, combination with chemotherapy
Anti-angiogenic
Bevacizumab (Avastin) Monoclonal antibody III First-line; combination with chemotherapy and trastuzumab
Sunitinib (Sutent) TKI II First- and second-line; combination with trastuzumab±chemotherapy
Pazopanib (Votrient) TKI II First-line; combination with lapatinib
Other strategies
Tanespimycin (17-AAG) Hsp90 inhibitor II
b First- and second-line (after trastuzumab progression); combination with trastuzumab
Retaspimycin (IPI-504) Hsp90 inhibitor II Relapsed (after trastuzumab progression); combination with trastuzumab
AUY922 Hsp90 inhibitor I/II Relapsed (after trastuzumab progression); monotherapy, combination with trastuzumab
BKM120 Pan-PI3K inhibitor I/II Relapsed (after trastuzumab progression); combination with trastuzumab
BEZ-235 PI3K/mTOR dual inhibitor I/II Relapsed (after trastuzumab progression); monotherapy, combination with
trastuzumab; in PIK3CA and/or PTEN mutation-positive patients only
Everolimus (RAD001, afinitor) mTOR inhibitor III First-line and relapsed (after trastuzumab resistance+taxane); combination with
chemotherapy+trastuzumab
BMS-754807 IGF-1R inhibitor I/II Relapsed (after trastuzumab failure); combination with trastuzumab
Cixutumumab (IMC-A12) IGF-1R inhibitor II Relapsed (after trastuzumab and chemotherapy); combination with capecitabine/lapatinib
Abbreviations: HER¼human epidermal growth factor receptor; hsp90¼heat shock protein 90; IGF-1R¼insulin-like growth factor-1 receptor; mTOR¼mammalian target of
rapamycin; TKI¼tyrosine kinase inhibitor; T-DM1¼trastuzumab DM1.
aSpecific to breast cancer only, unless otherwise indicated.
bFurther clinical development has been halted.
Table 2 Ongoing phase III clinical trials of investigational agents in HER2-positive metastatic breast cancer
Trial Setting Treatment regimen
Target
accrual Status
a
Pertuzumab
CLEOPATRA (NCT00567190) First-line Trastuzumab/docetaxel/pertuzumab vs
trastuzumab/docetaxel/placebo
808 Active, no
longer recruiting
T-DM1
MARIANNE (NCT01120184) First-line Trastuzumab+taxane (docetaxel or paclitaxel)
vs T-DM1+pertuzumab vs T-DM1+placebo
1,092 Recruiting
EMILIA (NCT00829166) Relapsed (after trastuzumab+taxane) T-DM1 vs lapatinib+capecitabine 980 Recruiting
NCT01419197 Relapsed (progression after X2 prior
HER2-targeted therapies)
T-DM1 vs treatment of physician’s choice 795 Recruiting
Afatinib
LUX-Breast 1 (NCT01125566) Second-line (after trastuzumab
progression)
Afatinib+vinorelbine vs
trastuzumab+vinorelbine
780 Recruiting
Everolimus
BOLERO-1 (NCT00876395) First-line Trastuzumab/paclitaxel/everolimus vs
trastuzumab/paclitaxel/placebo
717 Recruiting
BOLERO-3 (NCT01007942) Relapsed (after trastuzumab
resistance+taxane)
Trastuzumab/vinorelbine/everolimus vs
trastuzumab/vinorelbine/placebo
572 Recruiting
Abbreviations: HER¼human epidermal growth factor receptor; T-DM1¼trastuzumab DM1.
aClinicalTrials.gov accessed October 14, 2011.
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previously received a median of seven prior systemic agents
(including an anthracycline, taxane, capecitabine, trastuzumab and
lapatinib); an objective RR of 32.7% and a CBR of 44.5% were
reported (Krop et al, 2009a). Good patient tolerability to T-DM1
was seen, with thrombocytopenia, fatigue, and nausea being the
most common adverse events (AEs), and no dose-limiting
cardiotoxicities. Recently, preliminary results from a randomised
phase-II trial of T-DM1 vs trastuzumab/docetaxel in first-line,
HER2-positive MBC were presented (Perez et al, 2010). In 137
patients with a median follow-up of 6 months, single-agent T-DM1
achieved an objective RR of 47.8%, as compared with 41.4% for the
trastuzumab/docetaxel arm. A more favorable safety profile was
observed with the T-DM1 arm, with a lower incidence of grade 3
and 4 AEs (37.3% vs 75.0%). A recent update of these data also
demonstrated a significant increase in investigator-reported PFS
with T-DM1 compared with the control arm (14.2 vs 9.2 months,
respectively (Hurvitz et al, 2011). Preliminary data from a single-
arm phase-Ib/II trial evaluating the combination of pertuzumab
and T-DM1 in patients with previously untreated (n¼21) and
relapsed (n¼46) HER2-positive MBC showed a RR of 57.1% in
previously untreated patients (majority had received trastuzumab
(86%), taxanes (71%) and anthracyclines (62%) in the adjuvant
setting) and a RR of 34.8% in patients with relapsed disease (Dieras
et al, 2010). T-DM1 plus pertuzumab appeared to be well-tolerated
overall, although cardiotoxicity was observed with LVEF declines
in two patients. The results of large global phase-III trials
of T-DM1, including T-DM1 vs lapatinib plus capecitabine in
patients previously treated with a taxane and trastuzumab
(EMILIA; NCT00829166), as well as a three-arm trial evaluating
T-DM1 vs T-DM1/pertuzumab vs trastuzumab/taxane in the first-
line setting (MARIANNE; NCT01120184), are eagerly awaited.
HER-FAMILY TKIS – LAPATINIB, NERATINIB AND
AFATINIB
Lapatinib
Lapatinib (Tykerb; GlaxoSmithKline, London, UK) is a small
molecule, reversible, dual inhibitor of EGFR/HER1 and HER2,
currently approved by the US Food and Drug Administration for
use in MBC. Preclinical studies demonstrated potent antitumour
effects in HER2-overexpressing models, including in cell lines with
acquired trastuzumab resistance (Rusnak et al, 2001; Xia et al,
2002; Konecny et al, 2006). In phase-I and -II trials of single-agent
lapatinib in patients with HER2-positive breast cancer refractory to
trastuzumab, lapatinib exhibited modest clinical activity and a
tolerable toxicity profile (diarrhoea and rash) (Burris et al, 2005;
Burstein et al, 2008b; Blackwell et al, 2009). The pivotal phase-III
trial evaluated the combination of lapatinib (1250mg daily) plus
capecitabine (2000mgm
 2 daily, given on days 1–14 of a 21-day
cycle) vs capecitabine alone in patients with HER2-positive locally
advanced or MBC who were treatment refractory to an anthracy-
cline, taxane and trastuzumab (Geyer et al, 2006). In this trial of
324 patients, lapatinib plus capecitabine resulted in a 4-month
improvement in median TTP (8.4 vs 4.4 months; hazard ratio
(HR)¼0.49; Po0.001). A higher RR also favoured the combina-
tion arm (22% vs 14%), although this was not statistically
significant. In the updated efficacy analyses, the improvement in
median TTP was confirmed (6.2 vs 4.3 months; HR¼0.57;
P¼0.00013), although no statistical differences in overall survival
were demonstrated (Cameron et al, 2008; Cameron et al, 2010).
Lapatinib was reasonably well tolerated, with an increased
incidence of diarrhoea and rash with the addition of capecitabine.
The EGF30008 trial (Johnston et al, 2009) was a phase-III trial that
evaluated letrozole plus lapatinib (n¼642) vs letrozole plus
placebo (n¼644) in treatment-naive post-menopausal patients
with hormone receptor-positive MBC. Among the 219 estrogen
receptor-positive, HER2-positive patients, a 5.2-month improve-
ment in the primary endpoint of median PFS was seen in the
lapatinib/letrozole arm (8.2 vs 3.0 months; HR¼0.71; P¼0.019).
Overall survival data are awaited. Interestingly, a biomarker
analysis of this study suggests there may be a role for HER-family
targeting with letrozole in HER2-negative ER low-expressing
tumours (Finn et al, 2009a). In the EGF30001 phase-III trial,
which evaluated lapatinib plus paclitaxel vs paclitaxel alone in the
first-line setting, a median TTP improvement of 11.3 weeks was
observed in the HER2-positive population (36.4 vs 25.1 weeks;
HR¼0.53), albeit on a subset analysis (Di Leo et al, 2008; Finn
et al, 2009b). Total HER2 blockade with lapatinib and trastuzumab
was also evaluated in a phase-III trial of lapatinib plus trastuzumab
vs lapatinib alone in patients with MBC who had received a median
of three prior trastuzumab-containing regimens, and an almost
4-week improvement in PFS (12.0 vs 8.1 weeks; HR¼0.73;
P¼0.008), as well as a doubling of CBR (24.7% vs 12.4%;
P¼0.01), were observed (Blackwell et al, 2010). Importantly, data
thus far only suggest a trend to overall survival improvement (51.6
vs 39.0 weeks; HR¼0.75; P¼0.106). Interim results of a phase-II
trial evaluating the combination of lapatinib and trastuzumab in
patients with HER2-positive MBC (cohort 1 (n¼40): no prior
lapatinib, trastuzumab or chemotherapy for metastatic disease and
41 year since adjuvant trastuzumab, if received; cohort 2 (n¼47):
one to two prior lines of chemotherapy, including trastuzumab, or
relapse within 1 year of adjuvant trastuzumab) were recently
presented and showed objective RRs of 41.7% and 25% in cohorts
1 and 2, respectively (Lin et al, 2011). Grade 3/4 treatment-related
toxicities were described as uncommon, with grade 3 diarrhoea
reported in 7% and all others (not specified) in o3% of patients.
Neratinib
Neratinib (HKI-272; Pfizer, New York, NY, USA) is an irreversible,
oral small-molecule TKI of EGFR/HER1, HER2 and HER4
(Rabindran et al, 2004). In preclinical HER2 models, anti-
proliferative effects were accompanied by G1 cell-cycle arrest
and decreased downstream signal transduction (Rabindran et al,
2004). In a phase-I study of neratinib in advanced solid
malignancies, partial response was seen in 8 out of 25 (32%)
HER2-positive breast cancer patients who were previously treated
with trastuzumab, anthracyclines and taxanes (Wong et al, 2009).
Diarrhoea was the dose-limiting toxicity at a maximum tolerated
dose of 320mg once daily. An open-label, phase-II multicenter trial
of single-agent neratinib in advanced HER2-positive breast cancer,
which enrolled both trastuzumab-refractory (n¼66) and trastu-
zumab-naive (n¼70) patients, demonstrated modest clinical
activity in both cohorts (Burstein et al, 2010). Objective RRs of
24% and 56% were seen in the trastuzumab-refractory and
trastuzumab-naive groups, respectively, with a median PFS of
22.3 and 39.6 weeks. At a dose of 240mg once daily, diarrhoea was
the most common grade 3/4 AE, occurring in up to 30% of patients
and necessitating dose reductions and/or symptomatic manage-
ment. No cases of grade 3 or 4 cardiotoxicity were observed
(Burstein et al, 2010). Currently, studies of single-agent neratinib
(neratinib vs lapatinib/capecitabine, NCT00777101) and neratinib
combinations (with capecitabine, NCT00741260; trastuzumab,
NCT00398567; paclitaxel, NCT00445458; vinorelbine, NCT00
706030; and neratinib/paclitaxel vs trastuzumab/paclitaxel,
NCT00915018) are under evaluation in HER2-positive MBC. The
clinical relevance of neratinib as a ‘pan-HER’ family inhibitor and
it being irreversible is yet to be proven.
Afatinib
Afatinib (BIBW 2992; Boehringer Ingelheim, Ingelheim, Germany), an
anilino–quinazoline-derived irreversible, oral small-molecule ErbB
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activity in early-phase trials of advanced solid tumours and
trastuzumab-refractory HER2-positive breast cancer (Hickish et al,
2009; Yap et al, 2010; Yamamoto et al, 2011). Preclinical data
showed low nanomolar potency for EGFR, HER2 and HER4
kinases (Yamamoto et al, 2011), as well as anti-proliferative effects
in HER2-dependent models (Li et al, 2008). In a phase-I trial of 53
patients with advanced solid tumours, antitumour efficacy was
reported with continuous once-daily dosing of afatinib, including
stable disease for X6 months in 1 breast cancer patient (receptor
status and prior therapy not specified) (Yap et al, 2010).
Gastrointestinal (diarrhoea and nausea/vomiting) and dermatolo-
gic AEs (rash and dry skin), as well as fatigue, were most common.
An open-label, single-arm phase-II study of afatinib in 41 patients
with HER2-positive MBC following trastuzumab failure demon-
strated partial responses in 4 patients and stable disease in
8 patients (maintained for at least four cycles) (Hickish et al, 2009).
At a dose of 50mg once daily, grade 3 rash (9.8%) and diarrhoea
(22%) were most common. Recently, a global phase-III trial of
afatinib in HER2-positive MBC was initiated (LUX-Breast 1;
NCT01125566), which is evaluating vinorelbine/afatinib vs vino-
relbine/trastuzumab in patients with prior trastuzumab therapy.
ANTI-ANGIOGENIC STRATEGIES – BEVACIZUMAB,
SUNITINIB AND PAZOPANIB
Bevacizumab
Preclinical and clinical studies in HER2-positive breast cancer have
reported positive associations between HER2 and vascular
endothelial growth factor (VEGF) expression levels (Yen et al,
2000; Yang et al, 2002; Konecny et al, 2004). In a phase-II trial
evaluating trastuzumab and the monoclonal anti-VEGF antibody
bevacizumab (Avastin, Genentech) in the first-line metastatic
setting, an objective clinical RR by the World Health Organization
criteria of 48% and a CBR of 60% were reported (Hurvitz et al,
2009). Cardiovascular toxicities, including hypertension (most
common AE), as well as declines in LVEF (15 grade 1/2, 1 grade 4),
and ulcer perforation were seen. Two ongoing phase-III trials,
AVEREL (docetaxel/trastuzumab±bevacizumab; NCT00391092)
and ECOG 1105 (carboplatin/paclitaxel/trastuzumab±bevacizumab;
NCT00520975), are evaluating the addition of bevacizumab to
chemotherapy and trastuzumab as first-line therapy in HER2-
positive MBC.
In a heavily pre-treated HER2-positive MBC population (median
of four prior chemotherapies, three prior biological and two prior
hormonal therapies) of which 47 out of 52 (90%) received prior
trastuzumab, a phase-II study of lapatinib plus bevacizumab
reported a modest overall RR of 13% (Dickler et al, 2008).
Diarrhoea and rash, attributable to lapatinib use, were the most
common AEs. Declines in LVEF were also observed in this trial
(two grade 1 and three grade 2).
VEGFR TKIs
Sunitinib (Sutent; Pfizer) is an oral, multitargeted TKI against
VEGFR, platelet-derived growth factor receptor and stem cell
factor receptor (c-kit). In an open-label phase-II study of sunitinib
monotherapy in patients with MBC previously treated with taxanes
and anthracyclines, an overall RR of 11% was observed (Burstein
et al, 2008a). However, no correlation between clinical response
and ER or HER2 status was found. At present, two early-phase
clinical trials are evaluating sunitinib/trastuzumab combinations
in HER2-positive breast cancer, including a phase-I trial of
sunitinib plus trastuzumab and docetaxel in the first-line setting
(NCT00372424) and a phase-II trial of sunitinib plus trastuzumab
in the second-line setting (NCT00243503).
Pazopanib (Votrient; GlaxoSmithKline) is an oral multitargeted
TKI against VEGFR-1/2/3, platelet-derived growth factor receptor
and c-kit. In a randomised phase-II study of pazopanib (400mg
per day) plus lapatinib (1000mg per day) vs lapatinib alone
(1500mg per day) in HER2-positive, locally advanced or MBC in
the first-line setting, an interim analysis of 114 evaluable patients
(total n¼141) demonstrated modest efficacy with the dual TKI
approach (Slamon et al, 2008). Pazopanib plus lapatinib yielded a
12-week progressive disease rate of 15.9% vs 36.8% for lapatinib
monotherapy (by investigator assessment). A secondary endpoint
of 12-week RR also favoured the combination arm at 44.9% vs
27.8% (by investigator assessment; 36.2% vs 22.2% by independent
assessment). AEs of diarrhoea, nausea, transaminitis, hyperten-
sion, fatigue and dysgeusia were potentiated with the pazopanib/
lapatinib combination, whereas hair color change was solely
observed in the dual TKI arm. Notably, four patients experienced
declines in LVEF (three asymptomatic and one symptomatic) with
the combined anti-HER2/VEGF strategy.
HSP90 INHIBITORS
A novel therapeutic approach involves targeting the hsp90
molecular chaperone, whose function includes regulating the
stability and maturation of various oncoproteins including HER2
(Trepel et al, 2010). Tanespimycin (17-AAG, KOS-953; Bristol-
Myers Squibb, New York, NY, USA), a first-generation geldana-
mycin derivative, has demonstrated robust antitumour activity in
preclinical models of HER2-positive breast cancer (Munster et al,
2001; Munster et al, 2002). A phase-I study of tanespimycin plus
trastuzumab was encouraging, and antitumour activity was
observed in patients with HER2-positive MBC (Modi et al, 2007).
In a subsequent single-arm phase-II trial of tanespimycin (IV
weekly) plus trastuzumab in patients with HER2-positive MBC and
disease progression following trastuzumab, an overall RR of 22%
and CBR of 59% were reported (Modi et al, 2011). Tanespimycin
was well-tolerated overall, with diarrhoea, fatigue, nausea and
headache as the most common toxicities. Although further
clinical development of tanespimycin has been halted, other
hsp90 inhibitors, including retaspimycin (IPI-504; Infinity
Pharmaceuticals, Cambridge, MA, USA) and AUY922 (Novartis,
Cambridge, MA, USA) are currently under evaluation in early-
phase clinical trials as single agents or in combination with
trastuzumab (NCT00817362, NCT00526045 and NCT01271920).
PI3K/AKT/MTOR PATHWAY MODULATION
Another strategy to combat trastuzumab resistance involves
modulation of the PI3K/Akt/mTOR pathway (Nahta and O’Regan,
2010). Evaluation of the mTOR inhibitor everolimus (RAD001,
Afinitor; Novartis) in HER2-positive breast cancer is the most
advanced in clinical development to date. In a preclinical study of
PTEN-deficient, trastuzumab-resistant in vitro and in vivo models,
the combination of everolimus and trastuzumab resulted in
enhanced antitumour effects (Lu et al, 2007). In phase-I trials,
promising clinical activity was reported with everolimus when
used in combination with paclitaxel/trastuzumab or vinorelbine/
trastuzumab in HER2-positive MBC (Andre et al, 2010; Jerusalem
et al, 2011). In the first trial, a phase-Ib dose-escalation study of
everolimus with weekly paclitaxel and trastuzumab, an overall RR
of 44% was reported among 27 evaluable patients (Andre et al,
2010). In all, 74% of patients experienced disease control for 46
months, with a median PFS of 34 weeks for the entire cohort. At
the established dose of 10mg per day, grade 3 and 4 neutropenia
were the most common AEs (52%). In the second phase-Ib trial,
which evaluated everolimus plus weekly vinorelbine and trastuzu-
mab in HER2-positive MBC patients pretreated with trastuzumab,
an overall RR of 19.1%, disease control rate of 83.0% and median
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(Jerusalem et al, 2011). Neutropenia (92%) and stomatitis (70%)
were the most common hematologic and nonhematologic toxicities,
respectively. Additionally, three patients developed febrile neutro-
penia and four patients received G-CSF support. Based on these
promising early-phase clinical data in HER2-positive MBC,
phase-III trials of trastuzumab/paclitaxel±everolimus in the
first-line setting (BOLERO-1; NCT00876395) and trastuzumab/
vinorelbine±everolimus in the trastuzumab-refractory setting
(BOLERO-3; NCT01007942) are in progress. Early-phase clinical
trials are currently evaluating modulation of the PI3K/Akt/mTOR
pathway with the use of PI3K/Akt inhibitors, including BKM120
(Novartis) and BEZ-235 (Novartis) (NCT00620594 and
NCT01132664). Preclinical studies with PI3K/Akt inhibitors
suggest increased activity in tumours with PIK3CA mutations
(Brachmann et al, 2009), identified in approximately 20 to 30% of
HER2-positive breast cancers (Saal et al, 2005; Stemke-Hale et al,
2008; Gonzalez-Angulo et al, 2011).
IGF-1R INHIBITORS
Crosstalk between HER2 and IGF receptor families leading to
activation of alternative signaling pathways has also been
implicated in trastuzumab resistance (Nahta et al, 2006).
Preclinical models of trastuzumab-resistant, HER2-positive breast
cancer have characterised restoration of trastuzumab sensitivity by
disrupting the IGF-1R/HER2 heterodimer, synergistic interactions
with trastuzumab and associated decreased downstream receptor
signaling with IGF-1R inhibition (Lu et al, 2001; Nahta et al,
2005; Esparis-Ogando et al, 2008). In phase-I trials of IGF-1R
monoclonal antibodies in advanced solid malignancies, these
agents appear to be well-tolerated overall, although toxicities of
thrombocytopenia and hyperglycemia were observed (Weroha and
Haluska, 2008). Currently, phase-I and -II studies of anti-IGF-1R
therapies are underway in patients with locally advanced or
metastatic HER2-positive breast cancer after trastuzumab failure,
including a phase-I/II study of the small-molecule inhibitor BMS-
754807 (Bristol-Myers Squibb) in combination with trastuzumab
(NCT00788333) and a phase-II study of capecitabine/lapatinib
with or without the monoclonal antibody cixutumumab (IMC-
A12; ImClone, Bridgewater, NJ, USA) in patients previously treated
with trastuzumab and an anthracycline and/or a taxane
(NCT00684983).
CONCLUSIONS
There is no doubt that trastuzumab has provided significant
clinical benefit in patients with HER2-positive breast cancer. Still,
primary (de novo) and secondary (acquired) resistance represents
a real clinical challenge. Lapatinib has demonstrated modest
clinical activity in this setting and highlights the importance of
ongoing HER2 blockade in trastuzumab-refractory states. Newer
HER-family TKIs that are both irreversible and target HER4 in
addition to EGFR and HER2 are being evaluated and may provide
superior outcomes in this population. Meanwhile, anti-VEGF
strategies, such as bevacizumab, have demonstrated promising
activity and phase-III results are eagerly awaited. Other investiga-
tional agents in HER2-positive MBC, including hsp90 and mTOR
inhibitors, utilise novel approaches to combat trastuzumab resistance
and have also shown promising activity in early-phase clinical trials.
IGF-1R inhibition is supported by biologic rationale in the setting of
trastuzumab resistance due to receptor crosstalk, but mature clinical
data are lacking. The two antibody-based HER2-directed approaches,
pertuzumab and T-DM1, have shown promising efficacy. Both agents
are currently under phase-III evaluation and have the potential to
establish new treatment paradigms.F i n a l l y ,o n g o i n gt r a n s l a t i o n a l
research is critical in the development of novel biomarkers predictive
of clinical benefit with these evolving targeted agents in HER2-
positive breast cancer in order to minimise untoward drug-related
toxicities and ultimately enhance patient outcomes.
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